Edwards Lifesciences Corporation
NYSE:EWMedical - Devices
+$0.49 today
- Market cap
- $60.51B
- Beta
- 0.87
- P/E (TTM)
- 46.2
- EPS (TTM)
- $1.89
Volume 3.92M
Average 5.02M
EW Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Edwards Lifesciences CorporationNYSE: EW
Deferred Revenue (Non-current) · Q2 FY2026 · quarter ended Jun 2026
Deferred revenue (non-current) remains negative
Q2 FY2026 deferred revenue (non-current) was $0, compared with $0 a year earlier.
Context
- Deferred revenue (non-current) amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Deferred revenue (non-current) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How EW compares with its peers on the latest reported figures
- EW's Jun 2026 deferred revenue (non-current) of $0 is the highest of the 6 companies compared; the peer median is $0.
- Deferred revenue (non-current) amounts to 0.0% of total assets for EW, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | -100.0% | +30.6% | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding EW) | $0 | -100.0% | +30.6% | 0.0% | |
Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 862.8M | 769M | 1.13B | 3.05B | 2.94B |
| Short-term Investments | 604M | 446.3M | 500.5M | 930.7M | 1.29B |
| Net Receivables | 664.9M | 699.1M | 828.1M | 727.4M | 912.1M |
| Inventory | 726.7M | 875.5M | 903.5M | 1.09B | 1.13B |
| Other Current Assets | 237.1M | 195.9M | 542.5M | 374.4M | 338.8M |
| Total Current Assets | 3.18B | 3.1B | 4.04B | 6.29B | 6.74B |
| Property, Plant & Equipment (Net) | 1.64B | 1.73B | 1.68B | 1.78B | 1.91B |
| Goodwill | 1.17B | 1.16B | 1.15B | 1.78B | 1.77B |
| Intangible Assets | 323.6M | 285.2M | 399.4M | 1.18B | 1.13B |
| Long-term Investments | 1.83B | 1.24B | 583.9M | 307.9M | 773.9M |
| Tax Assets | 246.7M | 484M | 749.4M | 992.1M | 1.14B |
| Other Non-current Assets | 110.8M | 299.1M | 774.3M | 732.4M | 234.9M |
| Total Non-current Assets | 5.32B | 5.2B | 5.33B | 6.77B | 6.96B |
| Total Assets | 8.5B | 8.29B | 9.36B | 13.06B | 13.7B |
| Account Payables | 204.5M | 201.9M | 186.6M | 197.4M | 227.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 24.5M |
| Tax Payables | 99.5M | 96.2M | 106.5M | 374.7M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 53.7M | 27.2M |
| Other Current Liabilities | 342.7M | 305M | 530.2M | 442.7M | 874.5M |
| Total Current Liabilities | 1.03B | 1.02B | 1.2B | 1.51B | 1.81B |
| Long-term Debt | 595.7M | 596.3M | 597M | 597.7M | 598.3M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 969.6M | 797.6M | 786.2M | 810.6M | 865M |
| Total Non-current Liabilities | 1.63B | 1.46B | 1.45B | 1.49B | 1.55B |
| Total Liabilities | 2.67B | 2.49B | 2.64B | 2.99B | 3.36B |
| Common Stock | 642M | 646.3M | 650.5M | 654.8M | 658.7M |
| Retained Earnings | 6.07B | 7.59B | 8.99B | 13.17B | 14.24B |
| Accumulated OCI | (157.7M) | (254.9M) | (242.8M) | (244.5M) | (238.3M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 69.4M | 64.5M | 0 |
| Total Equity | 5.84B | 5.81B | 6.72B | 10.06B | 10.34B |
| Total Debt | 690.3M | 691.3M | 685.1M | 700M | 705.4M |
| Net Debt | (172.5M) | (77.7M) | (447.2M) | (2.35B) | (2.23B) |
Edwards Lifesciences Corporation
NYSE:EW
Intrinsic Alpha fair value
Locked
Current Price
$105.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.